Is EU REDEMPLO Approval For Clinically Diagnosed FCS Patients Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?

Simply Wall St.07-02

In June 2026, Arrowhead Pharmaceuticals announced that the European Commission granted marketing authorization for REDEMPLO (plozasiran) as an adjunct to diet to reduce triglyceride levels in adults ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648074025?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-02 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648074025","market":"hk","top_or_hot":-1,"title":"Is EU REDEMPLO Approval For Clinically Diagnosed FCS Patients Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?","media":"Simply Wall St.","content":"<div>\n<p>In June 2026, Arrowhead Pharmaceuticals announced that the European Commission granted marketing authorization for REDEMPLO (plozasiran) as an adjunct to diet to reduce triglyceride levels in adults ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/is-eu-redemplo-approval-for-clinically-diagnosed-fcs-patient\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is EU REDEMPLO Approval For Clinically Diagnosed FCS Patients Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs EU REDEMPLO Approval For Clinically Diagnosed FCS Patients Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-02 19:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/is-eu-redemplo-approval-for-clinically-diagnosed-fcs-patient><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In June 2026, Arrowhead Pharmaceuticals announced that the European Commission granted marketing authorization for REDEMPLO (plozasiran) as an adjunct to diet to reduce triglyceride levels in adults ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/is-eu-redemplo-approval-for-clinically-diagnosed-fcs-patient\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/is-eu-redemplo-approval-for-clinically-diagnosed-fcs-patient","article_id":"2648074025","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/is-eu-redemplo-approval-for-clinically-diagnosed-fcs-patient","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648074025","pubTimestamp":1782992773,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In June 2026, Arrowhead Pharmaceuticals announced that the European Commission granted marketing authorization for REDEMPLO (plozasiran) as an adjunct to diet to reduce triglyceride levels in adults with familial chylomicronemia syndrome, supported by Phase 3 PALISADE data showing very large median triglyceride reductions and a marked drop in acute pancreatitis risk versus placebo.\nBecause REDEMPLO is the first and only siRNA therapy in the European Union for adults with FCS and does not...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation","BK4156":"煤与消费用燃料","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"欧盟对临床诊断的FCS患者的REDEMPLO批准是否会改变Arrowhead Pharmaceuticals(ARWR)的投资案例？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1.5},"content_text":"In June 2026, Arrowhead Pharmaceuticals announced that the European Commission granted marketing authorization for REDEMPLO (plozasiran) as an adjunct to diet to reduce triglyceride levels in adults with familial chylomicronemia syndrome, supported by Phase 3 PALISADE data showing very large median triglyceride reductions and a marked drop in acute pancreatitis risk versus placebo. Because REDEMPLO is the first and only siRNA therapy in the European Union for adults with FCS and does not require genetic confirmation of the disease, the approval broadens the eligible patient population and highlights the commercial and scientific potential of Arrowhead’s TRiM™ RNAi platform. We’ll now examine how REDEMPLO’s European approval, especially its ability to treat clinically diagnosed FCS patients, reshapes Arrowhead’s investment narrative. Uncover the next big thing with 21 elite penny stocks that balance risk and reward.AdvertisementArrowhead Pharmaceuticals Investment Narrative RecapTo own Arrowhead, you need to believe that its TRiM RNAi platform can translate into commercially meaningful, approved drugs while the company manages rising costs and partner dependence. The EC approval of REDEMPLO helps de-risk plozasiran in FCS and gives Arrowhead its first marketed product in Europe, but it does not eliminate near term risks around cash burn, reimbursement decisions, and execution on broader cardiometabolic indications that remain key to the story. Among recent developments, Arrowhead’s June 27 reclassification into larger Russell indices (including the Russell 1000 and Midcap benchmarks) is especially relevant. This shift reflects the company’s move into a more widely followed peer group and may increase passive ownership, potentially amplifying how future clinical, regulatory, and reimbursement updates for REDEMPLO and other TRiM programs feed into short term trading around key catalysts. Yet even as REDEMPLO’s approval broadens Arrowhead’s opportunity, investors should be aware that reimbursement pressure and payer decisions could... Read the full narrative on Arrowhead Pharmaceuticals (it's free!)Arrowhead Pharmaceuticals’ narrative projects $398.8 million revenue and $64.0 million earnings by 2028.Uncover how Arrowhead Pharmaceuticals' forecasts yield a $64.08 fair value, a 20% downside to its current price.Exploring Other PerspectivesARWR 1-Year Stock Price Chart Some of the lowest estimate analysts saw annual revenue falling about 15.9 percent and needing a rich 150 times 2029 earnings, so compared with concerns about reimbursement pressure their view of Arrowhead’s risk reward before the REDEMPLO news was much more pessimistic and is exactly why it can be useful for you to weigh very different scenarios side by side.Explore 3 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth 20% less than the current price!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.Curious About Other Options?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648074025","isCrawlerRequest":true}